CVE-2023-33365

Description

A path traversal vulnerability exists in Suprema BioStar 2 before 2.9.1, which allows unauthenticated attackers to fetch arbitrary files from the server's web server.

Category

7.5
CVSS
Severity: High
CVSS 3.1 •
EPSS 0.42%
Vendor Advisory supremainc.com
Affected: n/a n/a
Published at:
Updated at:

References

Link Tags
https://kb.supremainc.com/knowledge/doku.php?id=en:release_note_291 release notes vendor advisory
https://claroty.com/team82/disclosure-dashboard/cve-2023-33365 third party advisory

Frequently Asked Questions

What is the severity of CVE-2023-33365?
CVE-2023-33365 has been scored as a high severity vulnerability.
How to fix CVE-2023-33365?
To fix CVE-2023-33365, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2023-33365 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2023-33365 is being actively exploited. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.